PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Phase Holographic Imaging Announces Management Changes
Recent technical progress has led the Board of Directors of Phase Holographic Imaging (PHI) to decide to focus resources on the company’s clinical product development program. In relation to this, the Board of Directors has, in discussion with CEO Anders Månsson, decided to initiate the search for a new CEO to lead the ambitious development that lies ahead.
PostNews: Press Release
PHI announces last day of trading in BTA
PostNews: Press Release
Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ) 8 January 2025
Phase Holographic Imaging PHI AB (publ), held a general meeting on 8 January 2025. The following resolutions were made.
PostNews: Press Release
PHI announces outcome of rights issue
PostNews: Press Release
Founder and board member subscribes for shares in the ongoing rights issue
Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
PostNews: Press Release
PHI at Aktieportföljen Live, BioStock and Financial Stockholm
The subscription period in PHI AB’s fully secured rights issue, totalling SEK 64.3 million, is ongoing until 20 December 2024. The Company’s CEO, Anders Månsson, has during the last couple of weeks presented the Company and its future plans. For links to the presentations and the podcast, see below.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: PHI accelerates growth with record order
PHI recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.
BioStock: PHI’s CEO comments on the approved US listing
PHI has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
OTC Market Center in New York welcomes PHI
Our very own ‘big apple’ news — PHI’s shares (OTCQB:PHIXF) are now also trading on the US-OTCQB Market! Go and see some snapshots and our CEO Patrik speaking on this exciting new chapter.
Interview with John Moore
Meet John Moore, the proposed new board member for PHI. John’s extensive experience and visionary mindset make him an invaluable addition to our team. Let’s dive into his journey and what made him interested in PHI.
